Table 1.
Characteristics of solid organ transplant recipients who completed the third dose of a SARS-CoV-2 mRNA vaccine.
| Characteristics | Total Cohort after Second Dose | Responders after Third Dose |
Non-Responders after Third Dose |
p-Value |
|---|---|---|---|---|
| N | 395 | 261 (77.9%) | 74 (22.1%) | |
| Antibody concentration (median) | 7.1 (IQR 7.1–73.2) | 605.5 (IQR 157.3–1543.6) | <7.1 | <0.001 |
| Age (median) | 58.2 (IQR 48.0–66.9) | 58.1 (IQR 48.7–66.4) | 60.2 (IQR 54.4–71.1) | 0.036 |
| Sex (males) | 225 (58.4%) | 152 (58.9%) | 42 (56.8%) | 0.789 |
| BMI | 26.0 (IQR 23.0–29.1) | 26.0 (IQR 23.1–28.9) | 25.9 (IQR 21.9–29.7) | 0.544 |
| Time from Tx b to vaccine months(median) | 86.7 (IQR 50.3–159.3) | 95.5 (IQR 55.7–183.1) | 51.8 (IQR 25.9–127.9) | <0.001 |
| Organ transplant | <0.001 | |||
| Kidney | 281 (73.2%) | 182 (70.5%) | 58 (78.4%) | |
| Liver | 62 (16.2%) | 54 (20.9%) | 3 (4.1%) | |
| Heart | 18 (4.7%) | 12 (4.7%) | 3 (4.1%) | |
| Lung | 14 (3.7%) | 6 (2.3%) | 6 (8.1%) | |
| Combined a | 9 (2.3%) | 4 (1.6%) | 4 (5.4%) | |
| Immunosuppressive treatment | ||||
| Prednisolone | 95 (24.0%) | 55 (21.1%) | 26 (35.1%) | 0.020 |
| CNI c | 311 (78.7%) | 198 (75.9%) | 61 (82.4%) | 0.273 |
| Proliferation inhibitor d | 365 (92.4%) | 237 (90.8%) | 73 (98.7%) | 0.022 |
| mTOR inhibitor e | 1 (0.3%) | 1 (0.4%) | 0 (0%) | 1.000 |
Note: a Kidney/liver, kidney/heart, and heart/lung. b Transplantation. c Calcineurin inhibitor (CNI): tacrolimus and cyclosporine. d Proliferation inhibitors: mycophenolate and azathioprine. e Mammalian target of rapamycin inhibitor (mTORi): sirolimus or everolimus.